Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / G.I. and Other Associated Cancers Research Group / Discovered galectin-3 ligand as a serum biomarker of colon cancer

Discovered galectin-3 ligand as a serum biomarker of colon cancer

Discovered galectin-3 ligand as a serum biomarker of colon cancer with sensitivity 72% and specificity 80% based on blinded validation in standard reference set.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.